[手术治疗突肉瘤患者的瘤结果和预后因素]
Matías Novillo1, José I Albergo2, Iván Huespe3
1Servicio de Ortopedia y Traumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Medicina
|October 23, 2023
概括
突肉瘤是一种罕见的癌症,其5年生存率为67%,无事件生存率为48%. 高组织学等级和转移表明极端病例的预后不佳.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 肉瘤研究研究 肉瘤研究
背景情况:
- 突肉瘤是一种罕见的恶性瘤,发生率和预后各不相同.
- 最常见的是影响年轻人,经常发生在四肢.
- 已发表的瘤结局和突肉瘤的预后因素显示出相当大的差异.
研究的目的:
- 分析43名被诊断为四肢突肉瘤的患者的外科治疗结果.
- 为了确定全球生存率,无事件生存率和局部复发率.
- 识别与不良预后相关的瘤风险因素.
主要方法:
- 对43名经过手术治疗的四肢突肉瘤患者的回顾性分析.
- 全球生存率,无事件生存率和局部复发率的评估.
- 统计分析以确定预后因素.
主要成果:
- 全球五年生存率为67% (CI 49-80%).
- 五年无事件生存率为48% (CI为32-52%).
- 五年局部复发率为25% (CI 13-46%);高组织学级和转移被确定为不良预后因素.
结论:
- 瘤学结果与先前发表的系列相一致.
- 高组织学等级和转移的存在是 extremity synovial sarcoma 的显著不良预后因素.
更多相关视频
相关概念视频
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


